carbocyanines and Carcinoma--Squamous-Cell

As a novel low-side-effect cancer therapy, photo-immunotherapy (PIT) is based on conjugating monoclonal antibody (mAb) with a near-infrared (NIR) phthalocyanine dye IRDye700DX (IR 700). IR700 is not only fluorescent to be used as an imaging agent, but also phototoxic. When illuminating with NIR light, PIT can induce highly-selective cancer cell death while leaving most of tumor blood vessels unharmed, leading to an effect termed super-enhanced permeability and retention (SUPR), which can significantly improve the effectiveness of anti-cancer drug. Currently, the therapeutic effects of PIT are monitored using 2D macroscopic fluorescence reflectance imager, which lacks the resolution and depth information to reveal the 3D distribution of mAb-IR700. In the study, we applied a multi-modal optical imaging approach including high-resolution optical coherence tomography (OCT) and high-sensitivity fluorescence laminar optical tomography (FLOT), to provide 3D tumor micro-structure and micro-distribution of mAb-IR700 in the tumor simultaneously during PIT in situ and in vivo. The multi-wavelength FLOT can also provide the blood vessels morphology of the tumor. Thus, the 3D FLOT reconstructed images allow us to evaluate the IR700 fluorescence distribution change with respect to the blood vessels and at different tumor locations/depths non-invasively, thereby enabling evaluation of the therapeutic effects in vivo and optimization of treatment regimens accordingly. The mAb-IR700 can access more tumor areas after PIT treatment, which can be explained by increased vascular permeability immediately after NIR-PIT. Two-photon microscopy was also used to record the mAb-IR700 on the tumor surface near the blood vessels to verify the results.

Topics: Animals; Antibodies, Monoclonal; Carbocyanines; Carcinoma, Squamous Cell; Cell Line, Tumor; Coloring Agents; Female; Fluorescence; Immunoconjugates; Immunotherapy; Infrared Rays; Mice; Mice, Nude; Microscopy, Fluorescence, Multiphoton; Organophosphorus Compounds; Phototherapy; Tomography, Optical; Tomography, Optical Coherence

Topics: Animals; Carbocyanines; Carcinoma, Squamous Cell; Cetuximab; Disease Models, Animal; Female; Humans; Hyaluronic Acid; Mice; Neoplasm Metastasis; Optical Imaging; Ovarian Neoplasms; Pathology, Surgical; Sentinel Lymph Node; Staining and Labeling; Trastuzumab

Esophageal tumors provide unique challenges and opportunities for developing and testing surveillance imaging technology for different tumor microenvironment components, including assessment of immune cell modulation, with the ultimate goal of promoting early detection and response evaluation. In this context, accessibility through the lumen using a minimally invasive approach provides a means for repetitive evaluation longitudinally by combining fluorescent endoscopic imaging technology with novel fluorescent nanoparticles that are phagocytized by immune cells in the microenvironment. The agent we developed for imaging is synthesized from Feraheme (ferumoxytol), a Food and Drug Administration-approved monocrystaline dextran-coated iron oxide nanoparticle, which we conjugated to a near-infrared fluorochrome, CyAL5.5. We demonstrate a high level of uptake of the fluorescent nanoparticles by myeloid-derived suppressor cells (MDSCs) in the esophagus and spleen of L2Cre;p120ctnflox/flox mice. These mice develop esophageal dysplasia leading to squamous cell carcinoma; we have previously demonstrated that dysplastic and neoplastic esophageal lesions in these mice have an immune cell infiltration that is dominated by MDSCs. In the L2Cre;p120ctnflox/flox mice, evaluation of the spleen reveals that nearly 80% of CD45+ leukocytes that phagocytized the nanoparticle were CD11b+Gr1+ MDSCs. After dexamethasone treatment, we observed concordant decreased fluorescent signal from esophageal lesions during fluorescent endoscopy and decreased CyAL5.5-fluorescent-positive immune cell infiltration in esophageal dysplastic lesions by fluorescence-activated cell sorting analysis. Our observations suggest that this translatable technology may be used for the early detection of dysplastic changes and the serial assessment of immunomodulatory therapy and to visualize changes in MDSCs in the esophageal tumor microenvironment.

Topics: Animals; Antineoplastic Agents, Hormonal; Carbocyanines; Carcinoma, Squamous Cell; Cells, Cultured; Dexamethasone; Dimethyl Sulfoxide; Endoscopy; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Ferrosoferric Oxide; Fluorescent Dyes; Indoles; Leukocyte Common Antigens; Leukocytes; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Nanoparticles; Spleen

The effectiveness of near-infrared imaging (NIR) interrogation of epidermal growth factor receptor (EGFR) expression as a sensitive biomarker of oral squamous cell carcinoma (OSCC) response to arsenic trioxide therapy was studied in mice.. A431 OSCC in vitro were exposed to 0 µM, 0.5 µM, 2.5 µM, or 5 µM of As(2)O(3) for 0 h, 24 h, 48 h and 72 h. Confocal microscopy and flow cytometry confirmed EGFR expression and demonstrated a sensitivity dose-related signal decline with As(2)O(3) treatment. Next, mice with pharynx-implanted A431 cells received As(2)O(3) i.p. every 48 h at 0.0, 0.5, 2.5, or 5 mg/kg/day (n = 6/group) from day 0 to 10. An intravenous NIR probe, EGF-Cy5.5, was injected at baseline and on days 4, 8, and 12 for dynamic NIR imaging. Tumor volume and body weights were measured three times weekly.. In vitro, A431 EGFR expression was well appreciated in the controls and decreased (p<0.05) with increasing As(2)O(3) dose and treatment duration. In vivo EGFR NIR tumor signal intensity decreased (p<0.05) in As(2)O(3) treated groups versus controls from days 4 to 12, consistent with increasing dosage. Tumor volume diminished in a dose-related manner while body weight was unaffected. Immunohistochemical staining of excised tumors confirmed that EGFR expression was reduced by As(2)O(3) treatment in a dose responsive pattern.. This study demonstrates for the first time that OSCC can be interrogated in vivo by NIR molecular imaging of the EGFR and that this biomarker is effective for the longitudinal assessment of OSCC response to As(2)O(3) treatment.

Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Body Weight; Carbocyanines; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gene Expression; Injections, Intraperitoneal; Injections, Intravenous; Magnetic Resonance Imaging; Mice; Mice, Nude; Mouth Neoplasms; Neoplasms, Experimental; Oxides; Recombinant Fusion Proteins; Spectroscopy, Near-Infrared; Tumor Burden; Tumor Cells, Cultured

Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein, we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis and therapy (cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as stability in serum, deformability, and rapid uptake by tumor cells. These properties are critical in increasing their tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these CNPs into novel theragnostic nanoparticles, we labeled them with Cy5.5, a near-infrared fluorescent (NIRF) dye, for imaging and also loaded them with paclitaxel (PTX-CNPs), an anticancer drug, for cancer treatment. Cy5.5 labeled PTX-CNPs exhibited significantly increased tumor-homing ability with low nonspecific uptake by other tissues in SCC7 tumor-bearing mice. Theragnostic nanoparticles, Cy5.5 labeled PTX-CNPs, are highly useful for simultaneous diagnosis of early-stage cancer and drug delivery.

Topics: Animals; Antineoplastic Agents, Phytogenic; Carbocyanines; Carcinoma, Squamous Cell; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Humans; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Paclitaxel

To evaluate cetuximab treatment in head and neck squamous cell carcinoma xenografts and cell lines, we investigated a preclinical model of head and neck squamous cell carcinoma. Head and neck squamous cell carcinoma cell lines SCC-1, FaDu, CAL27, UM-SCC-5 and UM-SCC-22A were used to generate subcutaneous flank xenografts in SCID mice. Mice were divided into control and cetuximab treatment groups, mice in the latter group received 250 μg cetuximab once weekly for four weeks. After completion of therapy, SCC-1 (p < 0.001), UM-SCC-5 (p < 0.001), UM-SCC-22A (p = 0.016) and FaDu (p = 0.007) tumors were significantly smaller than control, while CAL27 tumors were not different from controls (p = 0.90). Mice were systemically injected with 50 μg of the Cy5.5-cetuximab bioconjugate and imaged by stereomicroscopy to determine if tumor fluorescence predicted tumor response. Intact tumor fluorescence did not predict response. Tissue was harvested from untreated xenografts to evaluate ex vivo imaging. Cell lines were then evaluated in vitro for fluorescence imaging after Cy5.5-cetuximab bioconjugate labeling. The location of fluorescence observed in labeled cells was significantly different for cell lines that responded to treatment, relative to unresponsive cells. Tumors from cell lines that showed low internalized signal in vitro responded best to treatment with cetuximab. This preclinical model may aid in determining which cancer patients are best suited for cetuximab therapy.

Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carbocyanines; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Disease Models, Animal; ErbB Receptors; Fluorescent Antibody Technique; Fluorescent Dyes; Head and Neck Neoplasms; Humans; Mice; Mice, SCID; Microscopy, Fluorescence; Statistics, Nonparametric; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

In this report, we present the first case of a vulvar carcinosarcoma with squamous carcinomatous and leiomyosarcomatous differentiation. Comparative genomic hybridization was used to analyze clonality of the two tumor components. A widely identical pattern of genetic imbalances in the comparative genomic hybridization analysis in both the carcinomatous and the sarcomatous tumor component strongly supported the concept of a bidirectionally differentiated neoplasm. In both tumor components and two lymph node metastases, an amplicon was detected on chromosome 11q12-q13, homing the cyclin D1 gene locus. In contrast, exclusively in the sarcomatoid component, a characteristic amplicon on 12q13-q14 was found. The cytogenetic profile of the lymph node metastases revealed an increase in imbalances compared with the primary tumor. In summary, we found strong indications for a clonal origin of the two tumor components in a vulvar carcinosarcoma and a good correlation of the histological morphology with the pattern of genetic imbalances.

Topics: Aged; Biomarkers, Tumor; Carbocyanines; Carcinoma, Squamous Cell; Carcinosarcoma; Cell Differentiation; Chromosome Aberrations; Chromosomes, Human, Pair 12; Clone Cells; DNA, Neoplasm; Eosine Yellowish-(YS); Fatal Outcome; Female; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Hematoxylin; Humans; Immunohistochemistry; In Situ Hybridization; Indoles; Leiomyosarcoma; Lymph Node Excision; Lymphatic Metastasis; Staining and Labeling; Vulvar Neoplasms

We have recently reported that apoptosis of T cells induced by squamous cell carcinoma of the head and neck (SCCHN) is partly Fas dependent. This tumor-induced T-cell death is mediated by the activities of caspase-8 and caspase-3 and is partially inhibited by antibodies to either Fas or Fas ligand. We report here that in contrast to apoptosis induced by agonistic anti-Fas antibody (Ab), the tumor-induced apoptotic cascade in Jurkat cells is significantly amplified by a mitochondrial loop. The involvement of mitochondria in tumor-induced apoptosis of T cells was demonstrated by changes in mitochondrial permeability transition as assessed by 3,3'-dihexiloxadicarbocyanine staining, by cleavage of cytosolic BID and its translocation to the mitochondria, by release of cytochrome c to the cytosol, and by the presence of active subunits of caspase-9 in Jurkat T cells cocultured with tumor cells. To further elucidate the significance of mitochondria in tumor-induced T-cell death, we investigated the effects of various inhibitors of the mitochondrial pathway. Specific antioxidants, as well as two inhibitors of mitochondria permeability transition, bongkrekic acid and cyclosporin A, significantly blocked the DNA degradation induced in Jurkat T cells by SCCHN cells. However, these inhibitors had no effect on cells triggered by anti-Fas Ab. Furthermore, a cell-permeable inhibitor of caspase-9, Ac-LEHD.CHO, which did not inhibit T-cell apoptosis induced by anti-Fas Ab, markedly inhibited apoptosis induced by etoposide or by coculture of Jurkat with SCCHN cells. These findings demonstrate that apoptotic cascades induced in Jurkat T lymphocytes by anti-Fas Ab or tumor cells are differentially susceptible to a panel of inhibitors of mitochondrial apoptotic events. It appears that besides the Fas-mediated pathway, additional mitochondria-dependent cascades are involved in apoptosis of tumor-associated lymphocytes. Inhibition of mitochondria-dependent cascades of caspase activation should be considered to enhance the success of immunotherapy or vaccination protocols in cancer.

Topics: Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Bongkrekic Acid; Carbocyanines; Carcinoma, Squamous Cell; Carrier Proteins; Caspase 9; Caspases; Coculture Techniques; Cyclosporine; Cytochrome c Group; Cytosol; DNA; Enzyme Activation; Enzyme Inhibitors; Etoposide; fas Receptor; Fluorescent Antibody Technique; Fluorescent Dyes; Head and Neck Neoplasms; Humans; Jurkat Cells; Lymphocytes; Microscopy, Fluorescence; Mitochondria; Oligopeptides; Protein Transport; Subcellular Fractions; T-Lymphocytes; Tumor Cells, Cultured

Radiation-induced reoxygenation of the SCCVII murine tumour was examined with the goal of determining whether rapid reoxygenation in this tumour occurs as a result of cell loss, redistribution of hypoxic cells within the tumour cord, a change in oxygen consumption rate, or a change in tumour perfusion. Six hours after exposure of the tumour to 10 Gy, oxygen diffusion distance, measured using tumour cubes incubated with a fluorescent hypoxia probe, had increased by about 20%, corresponding to a reduction of about 16% in oxygen consumption rate. Cell loss and redistribution within the tumour cord were negligible at this time. Hypoxic fraction, measured using the comet assay, indicated a significant decrease from 18% hypoxic cells in unirradiated tumours to 6% in tumours examined 6 h after 10 Gy. Changes in tumour perfusion were also measured using the dual fluorescent dye method which allows detection of regions undergoing transient fluctuations in perfusion. Six hours after 10 Gy, the percentage of blood vessels labeled with only one stain had decreased from 8.6% to 4.5%. Results indicate that the rapid reoxygenation of the SCCVII tumour following exposure to 10 Gy can be attributed, not to cell loss or redistribution, but to a decrease in oxygen consumption and an increase in tumour perfusion.

Topics: Animals; Benzimidazoles; Carbocyanines; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Diffusion; DNA Damage; DNA, Neoplasm; Fluorescent Dyes; Male; Mice; Mice, Inbred C3H; Mice, Inbred Strains; Neoplasm Transplantation; Oxygen; Oxygen Consumption; Regional Blood Flow

The search for improved photosensitizers for laser phototherapy of malignancies has led to the examination of a new group of carbocyanine dyes as effective fluorochromes. In this study, four carbocyanine dyes with different absorption maxima of 483 nm [DiOC6(3)], 545.5 nm (DiIC5(3)], 556.6 nm [DiSC5(3)], and 651.0 nm [DiSC3(5)] were tested in vitro. The kinetics of uptake and toxicity of these four dyes were assessed for P3 human squamous cell carcinoma, HT29 colon carcinoma, M26 melanoma, and TE671 fibrosarcoma cell lines at 15, 30, 45, 60, and 180 minutes after exposure with each dye. After sensitization with DiOC6(3), the P3 and M26 cell lines were also tested for phototherapy by treatment with 488-nm light from an argon laser. The results showed that these four carbocyanine dyes had rapid and significant uptake by the carcinoma cell lines with no toxicity at concentrations < 0.1 micrograms/mL. Nontoxic DiOC6(3) levels in sensitized tumor cells after laser phototherapy resulted in approximately 85% inhibition of P3 and approximately 95% inhibition of M26 cell lines by MTT assays. The results suggest that these carbocyanine dyes can be used for tumor photosensitization and wavelength-matched laser photodynamic therapy. Further in vivo studies will be necessary to define the clinical potential of carbocyanine dyes as tumor-targeting agents for phototherapy of cancer.

Topics: Adenocarcinoma; Argon; Benzothiazoles; Carbocyanines; Carcinoma, Squamous Cell; Cell Survival; Colonic Neoplasms; Fibrosarcoma; Fluorescent Dyes; Humans; Laser Therapy; Lung Neoplasms; Medulloblastoma; Melanoma; Neoplasms; Photochemotherapy; Tetrazolium Salts; Tumor Cells, Cultured